NESS-040C5

NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.[2]

NESS-040C5
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H33N3OS
Molar mass447.64 g·mol−1
3D model (JSmol)

See also

References

  1. Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
  2. Hanus LO, Mechoulam R. "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59. doi:10.2174/092986710790980096. PMID 20166928.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.